Inactive Instrument

Synthorx, Inc.

Equities

US87167A1034

Synthorx, Inc. Announces Resignation of Floyd Romesberg from the Board of Directors

September 13, 2019 at 04:06 pm

Synthorx, Inc. announced that on September 11, 2019, in connection with the commencement of his employment with the Company in the position of Distinguished Fellow, Floyd Romesberg, Ph.D. resigned from the Board of Directors of the Company, effective as of September 12, 2019.

Latest news about Synthorx, Inc.

Synthorx, Inc.(NasdaqGS:THOR) dropped from S&P Global BMI Index	20-01-24	CI
Synthorx, Inc.(NasdaqGM:THOR) dropped from S&P TMI Index	20-01-24	CI
Synthorx, Inc. Announces Executive Changes	20-01-23	CI
Synthorx, Inc.(NasdaqGS:THOR) dropped from NASDAQ Composite Index	20-01-23	CI
Sanofi completed the acquisition of Synthorx, Inc. from Avalon Ventures, LLC, Correlation Ventures, OrbiMed Advisors LLC, Medicxi Ventures (UK) LLP and others.	20-01-22	CI
Tesla gets Chinese boost, Boeing’s new troubles, scandal for Tesco…	19-12-23
Synthorx : Sanofi shares rally on new margin goals, narrower drug focus	19-12-10	RE
Synthorx : Sanofi ends research in diabetes, narrows units to spur profit	19-12-09	RE
European shares dragged down by Tullow Oil and weak China export data	19-12-09	RE
Synthorx : France's Sanofi to buy biotech firm Synthorx for $2.5 billion	19-12-09	RE
Synthorx : France's Sanofi to buy biotech firm Synthorx for $2.5 billion	19-12-09	RE
Sanofi entered into definitive agreement to acquire Synthorx, Inc. from Avalon Ventures, LLC, Correlation Ventures, OrbiMed Advisors LLC, Medicxi Ventures (UK) LLP and others for $2.2 billion.	19-12-08	CI
Synthorx, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-05	CI
Synthorx, Inc. to Present THOR-809 Data at the American College of Rheumatology Annual Meeting	19-11-05	CI
Synthorx to Present At the European Society for Medical Oncology 2019 Congress	19-09-23	CI
Synthorx, Inc. Announces Resignation of Floyd Romesberg from the Board of Directors	19-09-13	CI
Synthorx, Inc. Enters into a Sub-Sublease with Avelas Biosciences, Inc	19-09-04	CI
Synthorx, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-01	CI
Synthorx Initiates Patient Dosing in Australia and Announces Clearance of Investigational New Drug in the U.S. for Lead Immuno-oncology Product Candidate, THOR-707	19-07-24	CI
Synthorx, Inc.(NasdaqGS:THOR) added to S&P Global BMI Index	19-06-24	CI
Synthorx, Inc.(NasdaqGS:THOR) added to S&P Global BMI Index	19-06-24	CI
Synthorx, Inc.(NasdaqGS:THOR) added to S&P Global BMI Index	19-06-24	CI
Certain Common Stock of Synthorx, Inc. are subject to a Lock-Up Agreement Ending on 5-JUN-2019.	19-06-04	CI
Certain Stock Options of Synthorx, Inc. are subject to a Lock-Up Agreement Ending on 5-JUN-2019.	19-06-04	CI
Synthorx, Inc. to Present Preclinical Data Demonstrating the Potential Safety and Anti-Tumor Effects of its Lead Product Candidate, THOR-707 at the 2019 American Society of Clinical Oncology Annual Meeting	19-05-15	CI

Chart Synthorx, Inc.

Duration

Period

More charts

Company Profile

Sector

More about the company